Addex Therapeutics (ADXN) Income from Continuing Operations (2018 - 2026)
Addex Therapeutics (ADXN) posted Income from Continuing Operations of 2185898.72 for Q1 2026, up 4.72% sequentially from 2294122.41 in Q4 2025, and down 33.43% YoY from 3283784.71 in Q1 2025.
Addex Therapeutics (ADXN) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Addex Therapeutics has reported Income from Continuing Operations for 9 years, with the latest figure at 2185898.72 in Q1 2026.
- Quarterly Income from Continuing Operations fell 33.43% year-over-year to 2185898.72 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8817883.27 (down 38.42% YoY) and the FY2025 annual result came in at 8253040.36, down 47.89% from the prior year.
- Income from Continuing Operations advanced to 2185898.72 in Q1 2026 per ADXN's latest filing, from 2294122.41 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 6590049.23 in Q4 2022 and troughed at 7497775.44 in Q2 2022.
- A 5-year average of 1901409.87 and a median of 1763134.67 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations jumped 237.36% in 2022, then tumbled 798.08% in 2024.
- Over 5 years, Income from Continuing Operations stood at 6590049.23 in 2022, then slumped by 115.36% to 1012377.85 in 2023, then sank by 34.16% to 1358218.08 in 2024, then plunged by 68.91% to 2294122.41 in 2025, then climbed by 4.72% to 2185898.72 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 2185898.72, 2294122.41, and 1971711.48 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | -2.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.19 Mn |
| Dec 31, 2025 | -2.29 Mn |
| Sep 30, 2025 | -1.97 Mn |
| Jun 30, 2025 | -2.37 Mn |
| Mar 31, 2025 | -1.64 Mn |
| Dec 31, 2024 | -1.36 Mn |
| Sep 30, 2024 | -1.76 Mn |
| Jun 30, 2024 | -1.61 Mn |
| Mar 31, 2024 | -3.59 Mn |
| Dec 31, 2023 | -1.01 Mn |
| Sep 30, 2023 | -804,661.58 |
| Jun 30, 2023 | -579,883.88 |
| Mar 31, 2023 | -400,039.88 |
| Dec 31, 2022 | 6.59 Mn |
| Sep 30, 2022 | -4.25 Mn |
| Jun 30, 2022 | -7.50 Mn |
| Mar 31, 2022 | -5.59 Mn |
| Dec 31, 2021 | -4.80 Mn |
| Sep 30, 2021 | -3.92 Mn |
| Jun 30, 2021 | -5.14 Mn |